Yabao – K13
Our current partnership with Yabao Pharmaceutical is to advance the development and commercialization of K13, an interference peptide that we developed for the treatment of stroke. It has the potential to be the first- in-class PTEN- targeting neuroprotective agent for stroke patients. Yabao has rights for China only. We retain freedom to operate in the rest of the world.